Merbarone is an orally active topoisomerase II inhibitor with antitumor activity; it blocks topoisomerase II-mediated DNA cleavage without stabilizing the topoisomerase II-DNA covalent complex; it inhibits proliferation of L1210 cells in vitro (IC50 = 10 μM); it inhibits human topoisomerase IIα-catalyzed DNA relaxation (IC50 ≈ 40 μM) and globally suppresses topoisomerase II-mediated DNA cleavage (IC50 ≈ 50 μM); it shows in vivo antitumor efficacy in murine leukemia models, achieving a maximum increased lifespan (ILS) of 101% in P388 leukemia at 50 mg/kg (daily i.p. for 5 days) and exhibits antitumor activity in mice at 124 mg/kg (daily p.o. for 9 days).